ALK fusions in the pan-cancer setting: another tumor-agnostic target?

Anaplastic lymphoma kinase (ALK) alterations (activating mutations, amplifications, and fusions/rearrangements) occur in ~3.3% of cancers. ALK fusions/rearrangements are discerned in >50% of inflammatory myofibroblastic tumors (IMTs) and anaplastic large cell lymphomas (ALCLs), but only in ~0.2%...

Descripción completa

Detalles Bibliográficos
Autores principales: Shreenivas, Aditya, Janku, Filip, Gouda, Mohamed A., Chen, Hui-Zi, George, Ben, Kato, Shumei, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542332/
https://www.ncbi.nlm.nih.gov/pubmed/37773318
http://dx.doi.org/10.1038/s41698-023-00449-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542332/
https://www.ncbi.nlm.nih.gov/pubmed/37773318
http://dx.doi.org/10.1038/s41698-023-00449-x

Ejemplares similares